1
|
Danielak D, Krejčí T, Beránek J. Increasing the efficacy of abiraterone - from pharmacokinetics, through therapeutic drug monitoring to overcoming food effects with innovative pharmaceutical products. Eur J Pharm Sci 2022; 176:106254. [DOI: 10.1016/j.ejps.2022.106254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2022] [Revised: 07/02/2022] [Accepted: 07/02/2022] [Indexed: 11/03/2022]
|
2
|
Kanji H, Horiyama S, Kimachi T, Haginaka J. Determination of Abiraterone and Its Metabolites in Human Serum by LC-ESI-TOF/MS Using Solid-phase Extraction. ANAL SCI 2021; 37:1281-1287. [PMID: 33678729 DOI: 10.2116/analsci.21p035] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
We developed and validated a liquid chromatography-electrospray ionization-time of flight/mass spectrometry method for the determination of abiraterone (Abi) and its metabolites (Δ4-Abi, 3-keto-5α-Abi, 3α-OH-5α-Abi and 3β-OH-5α-Abi) in human serum using Abi-d4 as the internal standard. As a pretreatment procedure of serum samples, solid-phase extraction based on a silica-gel cartridge was used. The relative recovery of Abi and its metabolites was over the ranges of 84.5 - 109.2% at a concentration of 6.0 ng mL-1 for Abi and 0.6 ng mL-1 for its metabolites. The method was free from matrix effects. The calibration curve of Abi was linear over the range of 2.0 - 400 ng mL-1 and those of its metabolites over the ranges 0.2 - 40 ng mL-1. The results of the intra- and inter-day accuracy and precision data were within the FDA acceptance criteria. The optimized method was applied for the determination of Abi and its metabolites in human serum after oral administration of Abi acetate.
Collapse
Affiliation(s)
- Hiromi Kanji
- School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University
| | - Shizuyo Horiyama
- School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University
| | - Tetsutaro Kimachi
- School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University
| | - Jun Haginaka
- Institute for Biosciences, Mukogawa Women's University
| |
Collapse
|
3
|
Dai L, Lv P, He Y, Wang X, Chen L, Dai J. A Novel LC-MS Method for the Determination of Abiraterone in Rat Plasma and its Application to Pharmacokinetic Studies. CURR PHARM ANAL 2021. [DOI: 10.2174/2213337208666210816112837] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
High-Performance Liquid Chromatography (HPLC)-Ultraviolet (UV) and
Liquid Chromatography (LC)-Mass Spectrometry (MS)/MS methods have been used to analyse abiraterone
(ART); however, a single-quadrupole mass spectrometer with LC-MS systems has never
been used to analyse ART.
Objective:
The study aimed to establish a novel, simple assay of quantitating ART in rat plasma
through LC-MS.
Method:
The analytical procedure involved the extraction of ART and D4-ART (internal standard,
IS) from rat plasma through simple protein precipitation. Chromatographic separation was
achieved using an isocratic mobile phase (acetonitrile: 5 mM ammonium formate with 0.1% formic
acid, 50:50 v/v) at a flow rate of 0.30 mL/min on a Waters XBridge® C18 column with a total run
time of 5 min. LC-MS ion transitions monitored were 350.1 and 354.1 for ART and IS, respectively.
The method was validated, and the results met acceptance criteria.
Results:
The lower limit of quantitation achieved was 1 ng/mL, and linearity was 1-8000 ng/mL.
The intra- and inter-day precisions were 1.26%-14.20% and 5.49%-13.08%, respectively, in rat
plasma.
Conclusion:
LC-MS offers a novel, specific, sensitive, and accurate method for quantifying ART
and it was successfully applied to pharmacokinetic studies of ART in rats.
Collapse
Affiliation(s)
- Linzhi Dai
- School of Pharmacy, Chengdu Medical College, Chengdu, China
| | - Pei Lv
- Analytical Research Department, Chengdu Hyperway Pharmaceuticals Co., Ltd., Chengdu, China
| | - Yun He
- Dental Department, School of Preclinical Medicine, Chengdu University, Chengdu, China
| | - Xiaoli Wang
- Clinical School of Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Lili Chen
- Analytical Research Department, Chengdu Hyperway Pharmaceuticals Co., Ltd., Chengdu, China
| | - Jing Dai
- School of Pharmacy, Chengdu Medical College, Chengdu, China
| |
Collapse
|
4
|
Weiss TLD, Furtado CM, Antunes MV, Gössling G, Schwartsmann G, Linden R, Verza SG. A quick UPLC–MS/MS method for therapeutic drug monitoring of abiraterone and delta(4)‐abiraterone in human plasma. Biomed Chromatogr 2020; 34:e4947. [DOI: 10.1002/bmc.4947] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2020] [Revised: 06/19/2020] [Accepted: 07/09/2020] [Indexed: 11/10/2022]
Affiliation(s)
- Thaís Luise Dillenburg Weiss
- Graduate Program on Toxicology and Analytical Toxicology, Institute of Health Sciences University Feevale Novo Hamburgo Brazil
| | - Carolina Mesquita Furtado
- Graduate Program on Toxicology and Analytical Toxicology, Institute of Health Sciences University Feevale Novo Hamburgo Brazil
| | - Marina Venzon Antunes
- Graduate Program on Toxicology and Analytical Toxicology, Institute of Health Sciences University Feevale Novo Hamburgo Brazil
| | - Gustavo Gössling
- Oncology Department, Hospital de Clínicas de Porto Alegre Porto Alegre RS Brazil
| | | | - Rafael Linden
- Graduate Program on Toxicology and Analytical Toxicology, Institute of Health Sciences University Feevale Novo Hamburgo Brazil
| | - Simone Gasparin Verza
- Graduate Program on Toxicology and Analytical Toxicology, Institute of Health Sciences University Feevale Novo Hamburgo Brazil
| |
Collapse
|
5
|
Bouhajib M, Tayab Z. Evaluation of the Pharmacokinetics of Abiraterone Acetate and Abiraterone Following Single-Dose Administration of Abiraterone Acetate to Healthy Subjects. Clin Drug Investig 2019; 39:309-317. [DOI: 10.1007/s40261-019-00752-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
6
|
van Nuland M, Venekamp N, de Vries N, de Jong KAM, Rosing H, Beijnen JH. Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology. J Chromatogr B Analyt Technol Biomed Life Sci 2019; 1106-1107:26-34. [PMID: 30639947 DOI: 10.1016/j.jchromb.2019.01.001] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2018] [Revised: 12/31/2018] [Accepted: 01/02/2019] [Indexed: 10/27/2022]
Abstract
A liquid chromatography-mass spectrometry assay was developed and validated for simultaneous quantification of anti-hormonal compounds abiraterone, anastrozole, bicalutamide, Δ(4)-abiraterone (D4A), N-desmethyl enzalutamide, enzalutamide, Z-endoxifen, exemestane and letrozole for the purpose of therapeutic drug monitoring (TDM). Plasma samples were prepared with protein precipitation. Analyses were performed with a triple quadrupole mass spectrometer operating in the positive and negative ion-mode. The validated assay ranges from 2 to 200 ng/mL for abiraterone, 0.2-20 ng/mL for D4A, 10-200 ng/mL for anastrozole and letrozole, 1-20 ng/mL for Z-endoxifen, 1.88-37.5 ng/mL for exemestane and 1500-30,000 ng/mL for enzalutamide, N-desmethyl enzalutamide and bicalutamide. Due to low sensitivity for exemestane, the final extract of exemestane patient samples should be concentrated prior to injection and a larger sample volume should be prepared for exemestane patient samples and QC samples to obtain adequate sensitivity. Furthermore, we observed a batch-dependent stability for abiraterone in plasma at room temperature and therefore samples should be shipped on ice. This newly validated method has been successfully applied for routine TDM of anti-hormonal drugs in cancer patients.
Collapse
Affiliation(s)
- M van Nuland
- Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, the Netherlands; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
| | - N Venekamp
- Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, the Netherlands
| | - N de Vries
- Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, the Netherlands
| | - K A M de Jong
- Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, the Netherlands; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - H Rosing
- Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, the Netherlands
| | - J H Beijnen
- Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, the Netherlands; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands
| |
Collapse
|
7
|
Saka C. Chromatographic Methods for Determination of Drugs Used in Prostate Cancer in Biological and Pharmacological Samples. Crit Rev Anal Chem 2018; 49:78-99. [DOI: 10.1080/10408347.2018.1487776] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Affiliation(s)
- Cafer Saka
- School of Healthy, Siirt University, Siirt, Turkey
| |
Collapse
|
8
|
Choudhury AD, Gray KP, Supko JG, Harshman LC, Taplin ME, Pace AF, Farina M, Zukotynski KA, Bernard B, Kantoff PW, Pomerantz M, Sweeney C. A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate 2018; 78:10.1002/pros.23662. [PMID: 29882250 PMCID: PMC6286224 DOI: 10.1002/pros.23662] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/24/2018] [Accepted: 05/16/2018] [Indexed: 01/14/2023]
Abstract
BACKGROUND Cabozantinib can enhance the effect of abiraterone in preclinical prostate cancer models. This study aimed to define the recommended phase 2 dose (RP2D) and preliminary efficacy of abiraterone + cabozantinib in mCRPC. METHODS Patients with progressive mCRPC with 0-2 prior chemotherapy regimens but no prior CYP17A1 or MET inhibitor received abiraterone acetate at 1000 mg daily with prednisone 5 mg BID in combination with cabozantinib at 20, 40, or 60 mg daily in a dose-escalation 3 + 3 open-label phase 1 design (Part A). After tolerable doses were defined, cohorts were expanded to better define toxicity and efficacy (Part B). RESULTS There were no dose-limiting toxicities (DLTs) in the first 4 weeks at any of the three dose levels in Part A. Two of the three patients at the 60 mg dose level required dose reductions beyond cycle 2 due to fatigue. In Part B, nine more patients were accrued to each of the 20 and 40 mg doses. Of the 12 patients treated at the 40 mg dose, only one DLT (grade 3 Lipase elevation) was observed in cycle 1. The median time to radiographic progression was 12.88 months (95% CI:5.42- not estimated [NE]) in the 20 mg cohort and 22.01 months (95% CI:15.44-NE) in the 40 mg cohort. Median overall survival was 23.29 months (95% CI:19.06-NE) in the 20 mg cohort and 39.08 months (95% CI:17.38-NE) in the 40 mg cohort. CONCLUSIONS Based on tolerability and preliminary efficacy, 40 mg cabozantinib plus 1000 mg abiraterone daily is the RP2D.
Collapse
Affiliation(s)
- Atish D Choudhury
- Dana-Farber Cancer Institute, Boston, Massachusetts
- Harvard Medical School, Boston, Massachusetts
| | - Kathryn P Gray
- Dana-Farber Cancer Institute, Boston, Massachusetts
- Harvard T. H. Chan School of Public Health, Boston, Massachusetts
| | | | - Lauren C Harshman
- Dana-Farber Cancer Institute, Boston, Massachusetts
- Harvard Medical School, Boston, Massachusetts
| | - Mary-Ellen Taplin
- Dana-Farber Cancer Institute, Boston, Massachusetts
- Harvard Medical School, Boston, Massachusetts
| | | | | | | | | | | | - Mark Pomerantz
- Dana-Farber Cancer Institute, Boston, Massachusetts
- Harvard Medical School, Boston, Massachusetts
| | - Christopher Sweeney
- Dana-Farber Cancer Institute, Boston, Massachusetts
- Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
9
|
Quantitation of the anticancer drug abiraterone and its metabolite Δ(4)-abiraterone in human plasma using high-resolution mass spectrometry. J Pharm Biomed Anal 2018. [DOI: 10.1016/j.jpba.2018.03.012] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
10
|
van Nuland M, Hillebrand MJX, Rosing H, Schellens JHM, Beijnen JH. Development and Validation of an LC-MS/MS Method for the Simultaneous Quantification of Abiraterone, Enzalutamide, and Their Major Metabolites in Human Plasma. Ther Drug Monit 2018; 39:243-251. [PMID: 28490047 DOI: 10.1097/ftd.0000000000000387] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Abiraterone acetate and enzalutamide are 2 novel drugs for the treatment of metastatic castration-resistant prostate cancer. The metabolism of these drugs is extensive. Major metabolites are N-desmethyl enzalutamide, enzalutamide carboxylic acid, abiraterone N-oxide sulfate, and abiraterone sulfate; of which N-desmethyl enzalutamide is reported to possess antiandrogen capacities. A liquid chromatography-tandem mass spectrometry method for simultaneous quantification of abiraterone, enzalutamide, and the main metabolites has been developed and validated to support therapeutic drug monitoring. METHODS Human plasma samples of patients treated with abiraterone or enzalutamide were harvested at the clinic and stored at -20°C. Proteins were precipitated by acetonitrile, and the final extract was injected on a Kinetex C18 column and separated with gradient elution. Analytes were detected by liquid chromatography-mass spectrometry (Triple Quad 6500). RESULTS The method was validated over various linear ranges: 1-100 ng/mL for abiraterone, 5-500 ng/mL for enzalutamide and enzalutamide carboxylic acid, 10-1000 ng/mL for N-desmethyl enzalutamide, 30-3000 ng/mL for abiraterone N-oxide sulfate, and 100-10,000 ng/mL for abiraterone sulfate. Intra-assay and interassay variabilities were within ±15% of the nominal concentrations for quality control samples at medium and high concentrations and within ±20% at the lower limit of quantification, respectively. CONCLUSIONS The described method for simultaneous determination of abiraterone and enzalutamide was validated successfully and provides a useful tool for therapeutic drug monitoring in patients treated with these agents.
Collapse
Affiliation(s)
- Merel van Nuland
- *Department of Pharmacy and Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute and MC Slotervaart;†Division of Clinical Pharmacology, Department of Medical Oncology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands; and‡Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands
| | | | | | | | | |
Collapse
|
11
|
Benoist GE, van der Meulen E, Lubberman FJE, Gerritsen WR, Smilde TJ, Schalken JA, Beumer JH, Burger DM, van Erp NP. Analytical challenges in quantifying abiraterone with LC-MS/MS in human plasma. Biomed Chromatogr 2017; 31:10.1002/bmc.3986. [PMID: 28370076 PMCID: PMC6114173 DOI: 10.1002/bmc.3986] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2017] [Revised: 03/21/2017] [Accepted: 03/30/2017] [Indexed: 11/09/2022]
Abstract
A method was developed and validated to quantify abiraterone in human plasma. During assay development, several analytical challenges were encountered: limited stability in patient samples, adsorption to glass, coelution with metabolites and carry-over issues. Limited stability (2 h) was found for abiraterone in fresh plasma as well as whole blood at ambient temperature. When kept at 2-8°C, abiraterone in plasma was stable for 24 h and in whole blood for 8 h. Adsorption of abiraterone to glass materials was addressed by using polypropylene throughout the method. Carry-over was reduced to acceptable limits by incorporating a third mobile phase into the gradient. The chromatographic separation of abiraterone with its multiple metabolites was addressed by using a longer analytical column and adjusting the gradient. Abiraterone was extracted by protein precipitation, separated on a C18 column with gradient elution and analyzed with tandem quadrupole mass spectrometry in positive ion mode. A stable deuterated isotope was used as the internal standard. The assay ranges from 1 to 500 ng/mL. Within- and-between-day precisions and accuracies were below 13.4% and within 95-102%. This bioanalytical method was successfully validated and applied to determine plasma concentrations of abiraterone in clinical studies and in regular patient care for patients with metastatic castration-resistant prostate cancer.
Collapse
Affiliation(s)
| | - Eric van der Meulen
- Department of Pharmacy, Radboud university medical center, Nijmegen, Netherlands
| | | | - Winald R. Gerritsen
- Department of Medical Oncology, Radboud university medical center, Nijmegen, Netherlands
| | - Tineke J. Smilde
- Department of Medical Oncology, Jeroen Bosch Hospital, Den Bosch, Netherlands
| | - Jack A. Schalken
- Department of Urology, Radboud university medical center, Nijmegen, Netherlands
| | - Jan H. Beumer
- Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, United States of America
| | - David M. Burger
- Department of Pharmacy, Radboud university medical center, Nijmegen, Netherlands
| | - Nielka P. van Erp
- Department of Pharmacy, Radboud university medical center, Nijmegen, Netherlands
| |
Collapse
|
12
|
Chandra Reddy BJ, Sarada NC. Development and validation of a novel RP-HPLC method for stability-indicating assay of Abiraterone acetate. J LIQ CHROMATOGR R T 2016. [DOI: 10.1080/10826076.2016.1163500] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- B. Jala Chandra Reddy
- Department of Chemistry, School of Advanced Sciences, VIT University, Vellore, Tamil Nadu, India
| | - N. C. Sarada
- Department of Chemistry, School of Advanced Sciences, VIT University, Vellore, Tamil Nadu, India
| |
Collapse
|
13
|
Belleville T, Noé G, Huillard O, Thomas-Schoemann A, Vidal M, Goldwasser F, Alexandre J, Blanchet B. A HPLC-fluorescence method for the quantification of abiraterone in plasma from patients with metastatic castration-resistant prostate cancer. J Chromatogr B Analyt Technol Biomed Life Sci 2015; 989:86-90. [DOI: 10.1016/j.jchromb.2015.03.001] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2014] [Revised: 02/26/2015] [Accepted: 03/01/2015] [Indexed: 10/23/2022]
|
14
|
β-cyclodextrin Sensitized Spectrofluorimetry for the Determination of Abiraterone Acetate and Abiraterone. J Fluoresc 2013; 23:1279-86. [DOI: 10.1007/s10895-013-1261-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2013] [Accepted: 06/25/2013] [Indexed: 10/26/2022]
|
15
|
Khedr A, Darwish I, Bamane F. Analysis of abiraterone stress degradation behavior using liquid chromatography coupled to ultraviolet detection and electrospray ionization mass spectrometry. J Pharm Biomed Anal 2013; 74:77-82. [DOI: 10.1016/j.jpba.2012.09.024] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2012] [Revised: 09/21/2012] [Accepted: 09/23/2012] [Indexed: 10/27/2022]
|
16
|
Gurav S, Punde R, Farooqui J, Zainuddin M, Rajagopal S, Mullangi R. Development and validation of a highly sensitive method for the determination of abiraterone in rat and human plasma by LC-MS/MS-ESI: application to a pharmacokinetic study. Biomed Chromatogr 2011; 26:761-8. [DOI: 10.1002/bmc.1726] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2011] [Accepted: 09/10/2011] [Indexed: 01/02/2023]
Affiliation(s)
- Sandip Gurav
- Drug Metabolism and Pharmacokinetics; Jubilant Biosys Ltd; Industrial Suburb, Yeshwanthpur; Bangalore; 560 022; India
| | - Ravindra Punde
- Drug Metabolism and Pharmacokinetics; Jubilant Biosys Ltd; Industrial Suburb, Yeshwanthpur; Bangalore; 560 022; India
| | - Junaid Farooqui
- Drug Metabolism and Pharmacokinetics; Jubilant Biosys Ltd; Industrial Suburb, Yeshwanthpur; Bangalore; 560 022; India
| | - Mohd Zainuddin
- Drug Metabolism and Pharmacokinetics; Jubilant Biosys Ltd; Industrial Suburb, Yeshwanthpur; Bangalore; 560 022; India
| | - Sriram Rajagopal
- Drug Metabolism and Pharmacokinetics; Jubilant Biosys Ltd; Industrial Suburb, Yeshwanthpur; Bangalore; 560 022; India
| | - Ramesh Mullangi
- Drug Metabolism and Pharmacokinetics; Jubilant Biosys Ltd; Industrial Suburb, Yeshwanthpur; Bangalore; 560 022; India
| |
Collapse
|
17
|
Attard G, Reid AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26:4563-71. [PMID: 18645193 DOI: 10.1200/jco.2007.15.9749] [Citation(s) in RCA: 667] [Impact Index Per Article: 41.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
PURPOSE Studies indicate that castration-resistant prostate cancer (CRPC) remains driven by ligand-dependent androgen receptor (AR) signaling. To evaluate this, a trial of abiraterone acetate-a potent, selective, small-molecule inhibitor of cytochrome P (CYP) 17, a key enzyme in androgen synthesis-was pursued. PATIENTS AND METHODS Chemotherapy-naïve men (n = 21) who had prostate cancer that was resistant to multiple hormonal therapies were treated in this phase I study of once-daily, continuous abiraterone acetate, which escalated through five doses (250 to 2,000 mg) in three-patient cohorts. RESULTS Abiraterone acetate was well tolerated. The anticipated toxicities attributable to a syndrome of secondary mineralocorticoid excess-namely hypertension, hypokalemia, and lower-limb edema-were successfully managed with a mineralocorticoid receptor antagonist. Antitumor activity was observed at all doses; however, because of a plateau in pharmacodynamic effect, 1,000 mg was selected for cohort expansion (n = 9). Abiraterone acetate administration was associated with increased levels of adrenocorticotropic hormone and steroids upstream of CYP17 and with suppression of serum testosterone, downstream androgenic steroids, and estradiol in all patients. Declines in prostate-specific antigen >or= 30%, 50%, and 90% were observed in 14 (66%), 12 (57%), and 6 (29%) patients, respectively, and lasted between 69 to >or= 578 days. Radiologic regression, normalization of lactate dehydrogenase, and improved symptoms with a reduction in analgesic use were documented. CONCLUSION CYP17 blockade by abiraterone acetate is safe and has significant antitumor activity in CRPC. These data confirm that CRPC commonly remains dependent on ligand-activated AR signaling.
Collapse
Affiliation(s)
- Gerhardt Attard
- Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|